Caribou Biosciences Regains Compliance with Nasdaq Listing Rule

Strategic Insights -

Caribou Biosciences, a biotechnology company based in Berkeley, California, has filed a Form 8-K report with the U.S. Securities and Exchange Commission (SEC) on June 23, 2025, announcing that it has regained compliance with Nasdaq Listing Rule 5450(a)(1). The rule requires listed companies to maintain a minimum closing bid price of $1.00 per share. Caribou Biosciences' common stock had fallen below this threshold, but after meeting the requirements, the company has successfully regained compliance.

Key Takeaways:

  • Caribou Biosciences received a written notice from the Nasdaq Staff on June 18, 2025, indicating the company had regained compliance with Nasdaq Listing Rule 5450(a)(1).
  • The company's common stock had a closing bid price of $1.00 per share or greater from June 3, 2025, to June 17, 2025, meeting the rule's requirements.
  • Regaining compliance is a significant milestone for the company, allowing it to continue listing its shares on the Nasdaq Global Select Market.
  • Caribou Biosciences' President and CEO, Rachel E. Haurwitz, Ph.D., authorized the report on June 23, 2025.
  • The company's success in regaining compliance highlights its efforts to maintain good corporate governance practices.

Statistics:

  • June 18, 2025: Date of the Nasdaq Staff's written notice to Caribou Biosciences
  • June 3, 2025: Start date of the 14-day period during which the company's common stock maintained a closing bid price of $1.00 per share or greater
  • June 17, 2025: End date of the 14-day period
  • Tuesday, June 23, 2025: File date of the FORM 8-K report with the SEC

Sources:

  • U.S. Securities and Exchange Commission. (2025, June 23). FORM 8-K. Washington, D.C.